A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD
Trial details
- Registry ID
- NCT03508700
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSDNCT03508700 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2019-09-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |